Natural sciences

Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Life sciences, Natural sciences, Pharmaceutical industry, Drug discovery, Clinical research, Food and Drug Administration, Clinical pharmacology, Clinical trial, Pharmacology, Drug development, ADME

Having successfully completed our IND-enabling studies and Investigational Brochure we have taken a large step closer to launching human clinical trials for a potential treatment for this unmet medical need, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.

Key Points: 
  • Having successfully completed our IND-enabling studies and Investigational Brochure we have taken a large step closer to launching human clinical trials for a potential treatment for this unmet medical need, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
  • The IB includes the pre-clinical safety and efficacy data, the design for Phase 1 clinical trials and the informed consent to enroll subjects in the trial.
  • These study areas include the following: Safety Pharmacology, Toxicology, CMC (Chemistry Manufacturing and Control) activities, ADME (Absorption, Distribution, Metabolism and Excretion) and Genotoxicity.
  • said Michael Redmond, CEO of Odyssey Group International
    Odyssey Group International, Inc. (OTC: ODYY ) is a technology and asset acquisition company with a focus in the area of life saving medical solutions.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment

Retrieved on: 
Wednesday, August 4, 2021
Dosage forms, Chemical engineering, Pharmaceutical industry, Tablet, Natural sciences, Applied sciences, Chemistry

Lexaria Biosciences proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing.

Key Points: 
  • Lexaria Biosciences proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing.
  • The companys technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules.
  • Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide.
  • By cutting through the overload of information in todays market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

Oyster Point Pharma to Report Second Quarter 2021 Financial Results on August 5, 2021

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Medication, Pharmaceutical industry, Natural sciences, Health sciences, Aerie Pharmaceuticals, Two River

PRINCETON, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the market close.

Key Points: 
  • PRINCETON, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the market close.
  • To access the live call by phone, please dial (855) 548-1220 (US/Canada) or (602) 563-8619 (International).
  • Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • Despite the large prevalence of dry eye and the burden of the disease, there remains a significant unmet need for effective therapies.

Worldwide Pipeline Maintenance Services Industry to 2026 - Pipeline Repair & Maintenance Segment to Have a Significant Share in the Market - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Mining, Minerals, Oil, Gas, Manufacturing, Natural Resources, Energy, Other Manufacturing, Steel, Metallurgy, Physical sciences, Chemistry, Natural sciences, Corrosion, Corrosion prevention, Piping, BP

The corrosion repair systems include full circumferential welded sleeves, welded patches, composite reinforcements, and pipe section replacements.

Key Points: 
  • The corrosion repair systems include full circumferential welded sleeves, welded patches, composite reinforcements, and pipe section replacements.
  • One of the major drivers for corrosion repair services is the growing share of heavy crude.
  • Thus, the growing share of heavy crude is expected to drive the demand for corrosion repair services, during the forecast period.
  • Hence, this is expected to create new opportunities for additional pipeline capacity during the forecast period, thereby, boosting the pipeline maintenance services market in the region.

Global Active Calcium Silicate Market (2021 to 2028) - Trends, Outlook and Implications Across COVID Recovery Cases - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Chemicals, Plastics, Manufacturing, Chemistry, Physical sciences, Natural sciences, Chemical elements, Dietary minerals, Reducing agents, Antacids, Calcium silicate, Calcium, Market analysis, Silicon

Introduction to Active Calcium Silicate Markets, 2021

Key Points: 
  • Introduction to Active Calcium Silicate Markets, 2021
    The global Active Calcium Silicate market analysis report is a comprehensive study detailing the market analysis during 2021.
  • The focused Active Calcium Silicate market report emphasizes Active Calcium Silicate industry size, key events, Active Calcium Silicate market statistics, and key factors prominent in the Active Calcium Silicate industry forecast and leading companies.
  • Active Calcium Silicate market growth factors, restraints, opportunities and market trends
    Key factors shaping the future of Active Calcium Silicate markets, driving factors, short term, and long term challenges, and potential market opportunities ahead of market players and the factors affecting the Active Calcium Silicate market outlook are provided in detail.
  • Chapter 2 presents Active Calcium Silicate market trends, insights, challenges, niche opportunities across the industry
    Chapter 4 analyzes and forecasts the leading Active Calcium Silicate market types, applications, and countries
    Chapter 5 presents North America Active Calcium Silicate Market analysis and outlook to 2028 (Countries: US, Canada, Mexico)
    Chapter 6 presents Europe Active Calcium Silicate Market Analysis and Outlook to 2028 (Countries: Germany, UK, France, Spain, Italy, Others)
    Chapter 7 presents Asia Pacific Active Calcium Silicate Market Size Outlook to 2028 (Countries: China, Japan, India, South Korea, Others)
    Chapter 8 presents Latin America Active Calcium Silicate Market Analysis and Outlook to 2028 (Countries: Brazil, Argentina, Chile, Others)
    Chapter 9 presents the Middle East and Africa Active Calcium Silicate Market Analysis and Outlook to 2028 (Countries: Saudi Arabia, UAE, Middle East, South Africa, and Other Africa)
    Chapter 10 details the company profiles, their SWOT profiles, business analysis, financials, and other developments
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005482/en/

Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Nucleic acids, Spherical nucleic acid, SNA, Biotechnology, Natural sciences

Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:30pm ET.

Key Points: 
  • Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:30pm ET.
  • BTIG hosted events are intended for prospective and existing BTIG clients only.
  • To listen to the live event, please contact your BTIG representative with interest.
  • Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology.

ElectroClave UV-C Disinfection System Chosen as Infection Prevention Solution for HiMSS21 Healthcare Conference In Las Vegas, NV

Retrieved on: 
Wednesday, August 4, 2021
Physical sciences, Chemistry, Hygiene, Natural sciences, Ultraviolet radiation, Biocides, Electromagnetic radiation, Electromagnetic spectrum, Ultraviolet, Sterilization, Ozone, Disinfectant

Seal Shield's revolutionary ElectroClave UV-C disinfection systems will be positioned throughout the conference for convenient sterilization of cell phones, tablets, badge readers and other mobile devices.

Key Points: 
  • Seal Shield's revolutionary ElectroClave UV-C disinfection systems will be positioned throughout the conference for convenient sterilization of cell phones, tablets, badge readers and other mobile devices.
  • The ElectroClave by Seal Shield is an unmatched UV-C LED disinfection system, providing 360-degree disinfection of mobile devices and high-touch items with 0% material degradation and zero ozone emissions.
  • Originally designed to combat the rate of hospital-acquired infections (HAIs) within healthcare, the ElectroClave now serves as an all-in-one solution for high level disinfection and management of mobile devices.
  • Seal Shield designs, develops, and manufactures advanced Infection Prevention solutions, including waterproof keyboards and mice, multilayer screen protectors, and advanced UV-C technology.

Enertopia Answers Your Provisional Patent Questions

Retrieved on: 
Wednesday, August 4, 2021
Physical sciences, Chemistry, Natural sciences, Patent law, United States patent law, Provisional application, Patent, Adsorption, Lithium

The first provisional patent ENERTOPIA SOLAR BOOSTER adsorbs the radiant heat energy from the solar array panels, heats the water running through the jacket, then deposits it into a storage tank to be reheated.

Key Points: 
  • The first provisional patent ENERTOPIA SOLAR BOOSTER adsorbs the radiant heat energy from the solar array panels, heats the water running through the jacket, then deposits it into a storage tank to be reheated.
  • This is done via provisional patent ones glazed adsorber, which heats the claystone solution to the required process heat temperature for extracting the Lithium.
  • One has twelve months from the filing date of a provisional patent to file for patent-pending paperwork.
  • There can be no assurance that patent #6,024,086 will have a positive impact on Enertopia.

Iridium announces partnership with Canadian Coast Guard

Retrieved on: 
Wednesday, August 4, 2021
Physical sciences, Satellite telephony, Chemistry, Natural sciences, Satellite Internet access, Iridium Communications, Iridium satellite constellation, Iridium, Metocean, Certus, Coast guard

MCLEAN, Va., Aug. 4, 2021 /PRNewswire/ -- Iridium Communications Inc. (NASDAQ:IRDM) today announced that the Canadian Coast Guard has adopted Iridium Certus connectivity with support from Iridium partner MetOcean Telematics .

Key Points: 
  • MCLEAN, Va., Aug. 4, 2021 /PRNewswire/ -- Iridium Communications Inc. (NASDAQ:IRDM) today announced that the Canadian Coast Guard has adopted Iridium Certus connectivity with support from Iridium partner MetOcean Telematics .
  • Iridium Certus delivers weather-resilient and completely global coverage, ensuring dependable connectivity in the high Arctic where the Coast Guard serves.
  • "The Canadian Coast Guard provides essential services that keep things moving safely in the Arctic waterways all year round," says Matt Desch, CEO, Iridium.
  • "MetOcean is pleased to support the communication efforts of the Canadian Coast Guard.

Iridium announces partnership with Canadian Coast Guard

Retrieved on: 
Wednesday, August 4, 2021
Physical sciences, Satellite telephony, Chemistry, Natural sciences, Satellite Internet access, Iridium Communications, Iridium satellite constellation, Iridium, Metocean, Certus, Coast guard

MCLEAN, Va., Aug. 4, 2021 /PRNewswire/ -- Iridium Communications Inc. (NASDAQ:IRDM) today announced that the Canadian Coast Guard has adopted Iridium Certus connectivity with support from Iridium partner MetOcean Telematics .

Key Points: 
  • MCLEAN, Va., Aug. 4, 2021 /PRNewswire/ -- Iridium Communications Inc. (NASDAQ:IRDM) today announced that the Canadian Coast Guard has adopted Iridium Certus connectivity with support from Iridium partner MetOcean Telematics .
  • Iridium Certus delivers weather-resilient and completely global coverage, ensuring dependable connectivity in the high Arctic where the Coast Guard serves.
  • "The Canadian Coast Guard provides essential services that keep things moving safely in the Arctic waterways all year round," says Matt Desch, CEO, Iridium.
  • "MetOcean is pleased to support the communication efforts of the Canadian Coast Guard.